伴有复杂核型的急性白血病患者的临床特征及其对预后的影响

doi:10.13481/j.1671-587x.20200228

摘要/Abstract

摘要： 目的：探讨复杂核型急性白血病（AL）患者的临床特征，初步阐明其与预后的关系。方法：选择33例复杂核型AL患者为研究对象（复杂核型组），从同时间诊断的248例非复杂核型AL患者中随机抽取43例患者作为对照（非复杂核型组）。收集2组患者的临床和实验室资料，分析临床特征及其与预后的关系。结果：与同期非复杂核型组比较，复杂核型组患者性别、年龄、治疗前的血液学指标、骨髓原始细胞比例及髓外浸润等差异均无统计学意义（P>0.05）；复杂核型AL在AL患者中的构成比为11.7%（33/281）。复杂核型组和非复杂核型组患者的完全缓解（CR）率分别为59.4%（19/32）和85.0%（34/40），二者比较差异有统计学意义（P=0.014）；复杂核型和非复杂核型急性髓系白血病（AML）患者CR率分别为47.6%（10/21）和79.3%（23/29），二者比较差异有统计学意义（P=0.020）；核型复杂程度高和核型复杂程度低的复杂核型AL患者CR率分别为41.2%（7/17）和80.0%（12/15），二者比较差异有统计学意义（P=0.036）。Kaplan-Meier生存分析，复杂核型组和非复杂核型组AL患者中位无复发生存时间（RFS）和中位总生存时间（OS）分别为162和462d（P=0.002）及256和769d（P<0.01），二者比较差异有统计学意义。AML和急性淋巴细胞白血病（ALL）患者中，复杂核型组和非复杂核型组患者中位OS分别为125和741d（P<0.01）及293和939d（P=0.008），二者比较差异有统计学意义。结论：复杂核型AL在AL患者中的构成比较低，一般临床特征无明显差异，但疗效及预后较差；复杂核型AL患者染色体复杂程度越高，疗效越差。

关键词: 急性白血病, 染色体, 复杂核型, 临床特征, 预后

Abstract: Objective: To investigate the clinical characteristics of the acute leukemia (AL) patients with complex karyotypes, and to elucidate their relationships with prognosis. Methods: A total of 33 AL patients with complex karyotypes were selected as the subjects (complex karyotype group), and 43 cases were randomly selected from 248 non-complex karyotype AL patients diagnosed at same time as the controls(non-complex karyotype group). The clinical and laboratory data of the patients in two groups were collected and the clinical characteristics and their relationships with prognosis were analyzed. Results: There were no significant differences in gender, age, hematological indexes before treatment, proportion of bone marrow primordial cells and extramedullary infiltration between the AL patients with complex karyotypes and non-complex karyotypes at same time (P>0.05); the constituent ratio of complex karyotypes AL in the AL patients was 11.7% (33/281).The complete remission (CR) rates of the AL patients in complex karyotype group and non-complex karyotype group were 59.4% (19/32) and 85.0% (34/40),there was significant difference between two groups (P=0.014); the CR rates of the acute myeloid leukemia (AML)patients in complex karyotype group and non-complex karyotype group were 47.6% (10/21) and 79.3% (23/29), there was significant difference between two groups (P=0.020).The CR rates of complex karyotypes AL patients with high karyotype complexity and low karyotype complexity were 41.2% (7/17) and 80.0% (12/15), there was significant difference between two groups(P=0.036).The Kaplan-Meier survival analysis showed that the median recurrence-free survival (RFS) and median overall survival (OS) of the patients in complex karyotype group and non-complex karyotype group were 162 and 462 d(P=0.002),256 and 769 d(P<0.01), and there were significant differences between two groups;the median OS of the AML and acute lymphoblastic leukemia(ALL) patients in complex karyotype group and non-complex karyotype group were 125 and 741 d (P<0.01), 293 and 939 d (P=0.008), and there were significant differences between two groups. Conclusion: The constituent ratio of complex karyotypes in the AL patients is relatively lower, and there are no significant differences in the general clinical characteristics, but the curative effect and prognosis are poor. The higher the chromosome complexity degree of the AL patients with complex karyotypes, the worse the curative effect.

Key words: acute leukemia, chromosome, complex karyotype, clinical feature, prognosis

中图分类号:

R733.71

宋红云, 潘莹, 安福润, 张家奎, 杨冬冬, 翟志敏. 伴有复杂核型的急性白血病患者的临床特征及其对预后的影响[J]. 吉林大学学报(医学版), 2020, 46(02): 377-382.

SONG Hongyun, PAN Ying, AN Furun, ZHANG Jiakui, YANG Dongdong, ZHAI Zhimin. Clinical characteristics of acute leukemia patients with complex karyotypes and their effects on prognosis[J]. Journal of Jilin University(Medicine Edition), 2020, 46(02): 377-382.

参考文献

[1] 刘艳春,李伟,王欢, 等.染色体核型动态监测对急性白血病患者化疗疗效评估的作用[J].中国实验血液学杂志,2015,23(3):658-662.
[2] BROWN P A,SHAH B,FATHI A,et al.NCCN guidelines insights:Acute lymphoblastic leukemia, version1.2017[J]. J Natl Compr Canc Netw,2017,15(9):1091-1102.
[3] O'DONNELL M R,TALLMAN M S,ABBOUD C N,et al. NCCN clinical practice guidelines in oncology:Acute myeloid leukemia, version3.2017[J]. J Natl Compr Canc Netw,2017,15(7):926-957.
[4] 中华医学会血液学分会白血病淋巴瘤学组.成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2017年版)[J].中华血液学杂志,2017,38(3):177-182.
[5] 中国抗癌协会血液肿瘤专业委员会,中华医学会血液学分会白血病淋巴瘤学组.中国成人急性淋巴细胞白血病诊断与治疗指南(2016年版)[J].中华血液学杂志,2016,37(10):837-845.
[6] NISHIWAKI S,MIYAMURA K,OHASHI K,et al.Impact of a donor source on adult Philadelphia chromosome-negative acute lymphoblastic leukemia:a retrospective analysis from the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation[J].Ann Oncol,2013,24(6):1594-1602.
[7] STRICKLAND S A,SUN ZX,KETTERLING R P,et al.Independent prognostic significance of monosomy 17 and impact of karyotype complexity in monosomal karyotype/complex karyotype acute myeloid leukemia:results from four ECOG-ACRIN prospective therapeutic trials[J].Leuk Res,2017,59:55-64.
[8] SEOL C A,CHO Y U,JANG S,et al.Prognostic significance of recurrent additional chromosomal abnormalities in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia[J].Cancer Genet,2017,216/217:29-36.
[9] BYRD J C,MRÓZEK K,DODGE R K,et al.Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:results from Cancer and Leukemia Group B (CALGB 8461)[J].Blood,2002,100(13):4325-4336.
[10] KURODA I,INUKAI T,ZHANG X,et al.BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia[J].Oncogene,2013,32(13):1670-1681.
[11] 张之南,沈悌.血液病诊断及疗效标准[J].3版.北京:科学出版社,2007:103-121.
[12] SCHWINGER E, LISA G,SHAFFER.Niels Tommerup:ISCN 2005:An international system for human cytogenetic nomenclature[J]. Ann Anat,2006,188(4):328.
[13] HAFERLACH C,ALPERMANN T,SCHNITTGER S,et al.Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia:a study on 824 cases with aberrant karyotype[J].Blood,2012,119(9):2122-2125.
[14] KAYSER S,ZUCKNICK M,DÖHNER K,et al.Monosomal karyotype in adult acute myeloid leukemia:prognostic impact and outcome after different treatment strategies[J].Blood,2012,119(2):551-558.
[15] STÖLZEL F,MOHR B,KRAMER M,et al.Karyotype complexity and prognosis in acute myeloid leukemia[J].Blood Cancer J,2016,6:e386.
[16] DANESHBOD Y,KOHAN L,TAGHADOSI V,et al.Prognostic significance of complex karyotypes in acute myeloid leukemia[J].Curr Treat Options Oncol,2019,20(2):15.
[17] SHI L H,MA P,LIU J S,et al.Current views of chromosomal abnormalities in pediatric acute myeloid leukemia (AML)[J].Eur Rev Med Pharmacol Sci,2017,21(4 Suppl):25-30.
[18] KAWAJIRI C,TANAKA H,HASHIMOTO S,et al.Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status[J].Int J Hematol,2014,99(4):513-518.
[19] 丁懿,李萍,张文君,等.同济96方案序贯治疗Ph染色体阴性成人急性淋巴细胞白血病疗效分析[J].中华血液学杂志,2015,36(4):272-276.
[20] KHORAL P,ATENAFU E G,CRADDOCK K J,et al.Prognostic effect of complex karyotype,monosomal karyotype, and chromosome 17 abnormalities in B-cell acute lymphoblastic leukemia[J].Clin Lymphoma Myeloma Leuk,2017,17(4):215-219.
[21] MRÓZEK K,MARCUCCI G,NICOLET D,et al.Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia[J].J Clin Oncol,2012,30(36):4515-4523.